+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 20Years - 90Years
All Genders
ID06372613

Determining Serum Leucine-rich Alpha 2-glycoprotein Levels That Predict Histologic Remission in Ulcerative Colitis Patients

Led by Showa Inan General Hospital · Updated on 2026-08-13

100

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying ulcerative colitis UC patients to understand how the level of serum leucine-rich alpha 2-glycoprotein LRG can predict histologic remission. LRG is being evaluated as a possible noninvasive biomarker to monitor disease activity in UC. The study aims to clarify the specific LRG level that indicates histologic remission in these patients. Participants with UC have their serum LRG levels measured using an enzyme-linked immunosorbent assay. Regardless of symptoms or LRG levels, participants undergo an annual colonoscopy with histologic examination. Disease activity is assessed by clinical remission using the partial Mayo score, endoscopic remission with the Mayo endoscopic subscore, and histologic remission defined by Geboes score. During the study, participants will have yearly colonoscopies and blood tests to measure LRG. The researchers analyze the diagnostic ability of LRG to predict histologic remission by comparing test results with biopsy findings. This observational study continues through 2027, monitoring outcomes such as histologic and endoscopic remission to better understand UC management.

CONDITIONS

Brief Title

Association Between LRG and Histologic Remission in Ulcerative Colitis

Research Team

A

Akia Horiuchi

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here